162 related articles for article (PubMed ID: 9834230)
21. New mechanism of organophosphorus pesticide-induced immunotoxicity.
Li Q
J Nippon Med Sch; 2007 Apr; 74(2):92-105. PubMed ID: 17507786
[TBL] [Abstract][Full Text] [Related]
22. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
LeFor AT; Eisenthal A; Rosenberg SA
J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603
[TBL] [Abstract][Full Text] [Related]
23. Later development of Fas ligand-mediated cytotoxicity as compared with granule-mediated cytotoxicity during the maturation of natural killer cells.
Nakazawa T; Agematsu K; Yabuhara A
Immunology; 1997 Oct; 92(2):180-7. PubMed ID: 9415024
[TBL] [Abstract][Full Text] [Related]
24. Evidence for the involvement of Fas ligand and perforin in the induction of vascular leak syndrome.
Rafi AQ; Zeytun A; Bradley MJ; Sponenberg DP; Grayson RL; Nagarkatti M; Nagarkatti PS
J Immunol; 1998 Sep; 161(6):3077-86. PubMed ID: 9743374
[TBL] [Abstract][Full Text] [Related]
25. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
Maas RA; Roest PA; Becker MJ; Weimar IS; Dullens HF; Den Otter W
Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728
[TBL] [Abstract][Full Text] [Related]
26. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous exposure to interleukin-18 and interleukin-10 in vitro synergistically augments murine spleen natural killer cell activity.
Micallef MJ; Tanimoto T; Torigoe K; Nishida Y; Kohno K; Ikegami H; Kurimoto M
Cancer Immunol Immunother; 1999; 48(2-3):109-17. PubMed ID: 10414464
[TBL] [Abstract][Full Text] [Related]
28. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
29. Differential effects of BCNU on T cell, macrophage, natural killer and lymphokine-activated killer cell activities in mice bearing a syngeneic tumor.
Nagarkatti M; Nagarkatti PS; Kaplan AM
Cancer Immunol Immunother; 1988; 27(1):38-46. PubMed ID: 3260820
[TBL] [Abstract][Full Text] [Related]
30. Heterogeneity of long-term cultured activated killer cells induced by anti-T3 antibody.
Yun YS; Hargrove ME; Ting CC
J Immunol; 1988 Aug; 141(4):1390-7. PubMed ID: 3260924
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of human cord blood CD34+ cell-derived NK cell cytotoxicity by dendritic cells.
Yu Y; Hagihara M; Ando K; Gansuvd B; Matsuzawa H; Tsuchiya T; Ueda Y; Inoue H; Hotta T; Kato S
J Immunol; 2001 Feb; 166(3):1590-600. PubMed ID: 11160200
[TBL] [Abstract][Full Text] [Related]
32. Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: a lethal two-way street.
Zeytun A; Hassuneh M; Nagarkatti M; Nagarkatti PS
Blood; 1997 Sep; 90(5):1952-9. PubMed ID: 9292529
[TBL] [Abstract][Full Text] [Related]
33. Regulation of perforin-independent NK cell-mediated cytotoxicity.
Wallin RP; Screpanti V; Michaëlsson J; Grandien A; Ljunggren HG
Eur J Immunol; 2003 Oct; 33(10):2727-35. PubMed ID: 14515256
[TBL] [Abstract][Full Text] [Related]
34. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
Vujanovic NL; Herberman RB; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411
[TBL] [Abstract][Full Text] [Related]
35. Inhibitory effects of alloimmune T cells on the generation of cytolytic responses of lymphokine-activated killer cells.
Sugarbaker PH; Matthews W; Steller EP; Eggermont AM
J Biol Response Mod; 1987 Aug; 6(4):430-45. PubMed ID: 3498012
[TBL] [Abstract][Full Text] [Related]
36. Perforin- and Fas-dependent mechanisms of natural killer cell-mediated rejection of incompatible bone marrow cell grafts.
Taylor MA; Ward B; Schatzle JD; Bennett M
Eur J Immunol; 2002 Mar; 32(3):793-9. PubMed ID: 11870623
[TBL] [Abstract][Full Text] [Related]
37. Tumor immunity in perforin-deficient mice: a role for CD95 (Fas/APO-1).
Rosen D; Li JH; Keidar S; Markon I; Orda R; Berke G
J Immunol; 2000 Mar; 164(6):3229-35. PubMed ID: 10706715
[TBL] [Abstract][Full Text] [Related]
38. Localization of Fas ligand in cytoplasmic granules of CD8+ cytotoxic T lymphocytes and natural killer cells: participation of Fas ligand in granule exocytosis model of cytotoxicity.
Kojima Y; Kawasaki-Koyanagi A; Sueyoshi N; Kanai A; Yagita H; Okumura K
Biochem Biophys Res Commun; 2002 Aug; 296(2):328-36. PubMed ID: 12163021
[TBL] [Abstract][Full Text] [Related]
39. Functional defects of NK cells treated with chloroquine mimic the lytic defects observed in perforin-deficient mice.
Austin Taylor M; Bennett M; Kumar V; Schatzle JD
J Immunol; 2000 Nov; 165(9):5048-53. PubMed ID: 11046034
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-12 up-regulates perforin- and Fas-mediated lymphokine-activated killer activity by intestinal intraepithelial lymphocytes.
Ebert EC
Clin Exp Immunol; 2004 Nov; 138(2):259-65. PubMed ID: 15498035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]